Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company's da Vinci surgical System translates a surgeon's natural hand movements, which are performed on instrument controls at a console into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. Its da Vinci surgical system include surgeon's consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. The company also manufactures EndoWrist instruments that include forceps, scissors, electrocautery, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures. In addition, it offers da Vinci Single-Site instruments and accessories that allow surgical systems to work through a single incision; and EndoWrist One vessel sealers that are wristed single-use instruments intended for bipolar coagulation and mechanical transection of vessels up to 7 mm in diameter and tissue bundles that fit in the jaws of the instrument. Further, the company provides EndoWrist stapler, a wristed stapling instrument intended for resection, transection, and/or creation of anastomoses, as well as sells various accessories, including replacement 3-D stereo endoscopes, camera heads, light guides, and other items that facilitate use of the da Vinci system, as well as sterile drapes for ensuring a sterile field during surgery. Intuitive Surgical, Inc. markets its products directly and through distributors in the United States, Europe, Asia, and internationally. The company was founded in 1995 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ISRG
Previous Symbol
CUSIP46120E60
Phone408-523-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio6.05
Quick Ratio5.52
Price-To-Earnings
Trailing P/E Ratio69.28
Forward P/E Ratio52.32
P/E Growth3.56
Sales & Book Value
Annual Sales$3.13 billion
Price / Sales18.18
Cash Flow$8.6583 per share
Price / Cash Flow57.53
Book Value$42.19 per share
Price / Book11.81
Profitability
EPS (Most Recent Fiscal Year)$7.19
Net Income$660 million
Net Margins22.31%
Return on Equity18.79%
Return on Assets15.97%
Miscellaneous
Employees4,444
Outstanding Shares114,200,000
Market Cap$56.15 billion
OptionableOptionable
Intuitive Surgical (NASDAQ:ISRG) Frequently Asked Questions
What is Intuitive Surgical's stock symbol?
Intuitive Surgical trades on the NASDAQ under the ticker symbol "ISRG."
When did Intuitive Surgical's stock split? How did Intuitive Surgical's stock split work?
Shares of Intuitive Surgical split on the morning of Friday, October 6th 2017. The 3-1 split was announced on Friday, August 11th 2017. The newly minted shares were payable to shareholders after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Intuitive Surgical stock prior to the split would have 300 shares after the split.
How were Intuitive Surgical's earnings last quarter?
Intuitive Surgical, Inc. (NASDAQ:ISRG) announced its earnings results on Thursday, October, 18th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $2.66 by $0.17. The medical equipment provider earned $920.90 million during the quarter, compared to analysts' expectations of $916.22 million. Intuitive Surgical had a return on equity of 18.79% and a net margin of 22.31%. The business's revenue was up 14.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.77 EPS. View Intuitive Surgical's Earnings History.
When is Intuitive Surgical's next earnings date?
What price target have analysts set for ISRG?
19 equities research analysts have issued 12-month target prices for Intuitive Surgical's stock. Their predictions range from $300.00 to $635.00. On average, they anticipate Intuitive Surgical's stock price to reach $558.3889 in the next year. This suggests a possible upside of 12.1% from the stock's current price. View Analyst Price Targets for Intuitive Surgical.
What is the consensus analysts' recommendation for Intuitive Surgical?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last year. There are currently 1 sell rating, 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intuitive Surgical.
What are Wall Street analysts saying about Intuitive Surgical stock?
Here are some recent quotes from research analysts about Intuitive Surgical stock:
- 1. According to Zacks Investment Research, "Intuitive Surgical expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company. On the brighter side, strong prospects in the company’s robotic platform – da Vinci System – is a positive. da Vinci procedures recorded solid growth in recent times. This is led by growth in U.S. general surgery procedures and global urologic procedures. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. The company outperformed the industry in a year’s time. " (12/6/2018)
- 2. BTIG Research analysts commented, "Procedures Accelerate Intuitive reported another strong quarter but this time procedures accelerated to ~20% y/y growth. On the procedure side, hernia continues to be the strongest growth contributor with management noting hernia is no longer in the first innings but has plenty of growth potential to come. Colorectal continued strong US growth while core GYN and prostate trends remained healthy in the US. OUS prostate growth paced Europe while Japan saw ~40% growth driven by newly established reimbursement. Systems again topped the Street but this includes a larger contribution from leases. We believe getting systems out in the field makes sense, but at the high valuation, some investors may not want to give full credit for leases that do not drive full ASPs up front." (10/21/2018)
- 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating on shares of ISRG and maintain our price target of $620. ISRG momentum continued as the company significantly beat all the metrics we track. ISRG delivered 20% procedure growth for 3Q18, the highest quarterly procedure growth since 2012. ISRG again raised full-year 2018 procedure growth guidance to 17-18% from 14.5-16.5%. The global installed based grew 13% and utilization was up by mid-single digits. The strong quarterly growth and expanding number of future growth drivers continue to justify ISRG’s premium valuation, in our view." (10/19/2018)
Has Intuitive Surgical been receiving favorable news coverage?
Media stories about ISRG stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intuitive Surgical earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an effect on the stock's share price in the next few days.
Who are some of Intuitive Surgical's key competitors?
Some companies that are related to Intuitive Surgical include Edwards Lifesciences (EW), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Smith & Nephew (SNN), Steris (STE), WILLIAM DEMANT/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX) and Invacare (IVC).
Who are Intuitive Surgical's key executives?
Intuitive Surgical's management team includes the folowing people:
- Dr. Gary S. Guthart, CEO, Pres & Director (Age 52)
- Mr. Marshall L. Mohr, Sr. VP & CFO (Age 62)
- Mr. Salvatore J. Brogna, Exec. VP & COO (Age 63)
- Mr. David J. Rosa, Exec. VP & Chief Commercial Officer (Age 50)
- Dr. Myriam J. Curet McAdams, Exec. VP & Chief Medical Officer (Age 61)
Who are Intuitive Surgical's major shareholders?
Intuitive Surgical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.28%), BlackRock Inc. (6.79%), FMR LLC (5.78%), Bank of New York Mellon Corp (2.60%), Capital World Investors (2.58%) and Morgan Stanley (2.50%). Company insiders that own Intuitive Surgical stock include Alan J Levy, Amal M Johnson, Colin Morales, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Keith R Leonard, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Institutional Ownership Trends for Intuitive Surgical.
Which major investors are selling Intuitive Surgical stock?
ISRG stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, American Century Companies Inc., MERIAN GLOBAL INVESTORS UK Ltd, Alliancebernstein L.P., Mitsubishi UFJ Trust & Banking Corp, Janus Henderson Group PLC, Cornerstone Wealth Management LLC and Point72 Asset Management L.P.. Company insiders that have sold Intuitive Surgical company stock in the last year include Amal M Johnson, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Insider Buying and Selling for Intuitive Surgical.
Which major investors are buying Intuitive Surgical stock?
ISRG stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Jennison Associates LLC, Mirae Asset Global Investments Co. Ltd., Capital World Investors, Rehmann Capital Advisory Group, BlackRock Inc., AQR Capital Management LLC and KAMES CAPITAL plc. View Insider Buying and Selling for Intuitive Surgical.
How do I buy shares of Intuitive Surgical?
Shares of ISRG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intuitive Surgical's stock price today?
One share of ISRG stock can currently be purchased for approximately $498.11.
How big of a company is Intuitive Surgical?
Intuitive Surgical has a market capitalization of $56.15 billion and generates $3.13 billion in revenue each year. The medical equipment provider earns $660 million in net income (profit) each year or $7.19 on an earnings per share basis. Intuitive Surgical employs 4,444 workers across the globe.
What is Intuitive Surgical's official website?
How can I contact Intuitive Surgical?
Intuitive Surgical's mailing address is 1020 KIFER ROAD, SUNNYVALE CA, 94086. The medical equipment provider can be reached via phone at 408-523-2100 or via email at [email protected]
MarketBeat Community Rating for Intuitive Surgical (NASDAQ ISRG)
MarketBeat's community ratings are surveys of what our community members think about Intuitive Surgical and other stocks. Vote "Outperform" if you believe ISRG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISRG will underperform the S&P 500 over the long term. You may vote once every thirty days.
